Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Although a rare disease, idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases (ILDs). Characterized by an irreversible loss of lung function, it is associated with a high morbidity and mortality rate; most patients die within three to five years following diagnosis. The etiology of IPF is unclear, but accumulating evidence suggests that it arises as a result of epithelial injury followed by abnormal wound healing. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT) approved for IPF, followed soon after by Boehringer Ingelheim’s nintedanib (Ofev)—setting the stage for fierce competition in the IPF therapy market. We explore this evolving space, analyzing the clinical and commercial outlook for pirfenidone and nintedanib and FibroGen’s emerging IV-administered IPF therapy pamrevlumab. We examine current medical practice and identify areas of pressing unmet need in the treatment of IPF. We also assess different market scenarios in which Galapagos’s GLPG-1690, an oral autotaxin inhibitor, is approved as a monotherapy or as an add-on therapy for IPF.
Already a Client? Log in to access this report.
Akash Saini, is a lead analyst with the Infectious, Niche, and Rare Disease team at Decision Resources Group. Prior to joining Decision Resources Group, Saini was a postdoctoral fellow at the University of Massachusetts Medical School, where he studied mitochondrial dysfunction in amyotrophic lateral sclerosis (ALS). He earned a in Biochemistry and Biotechnology from the International Centre for Genetic Engineering and Biotechnology, New Delhi, where he also studied the underlying disease mechanism in ALS, and an in Biotechnology from Jawaharlal Nehru University, New Delhi, where he studied the biophysical characteristics of amyloid formation.
Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.